Business
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":" LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.\n\nInvestor Conference Call:\n\nChromaDex management will host an investor conference call to discuss the first quarter results and provide a general business update on Thurs., May 12, at 4:30 p.m. ET.\n\nParticipants should call in at least 10 minutes prior to the call. The dial-in information is as follows:\n\nDate: Thurs., May 12, 2022\nTime: 4:30 p.m. ET (1:30 p.m. Pacific time)\nToll-free dial-in number: 1-888-330-2446\nConference ID: 4126168\nWebcast link: ChromaDex First Quarter 2022 Earnings Conference Call\n\nThe conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.\n\nA replay of the conference call will be available from 7:30 p.m. ET on May 12, 2022, to 11:59 p.m. ET on May 19, 2022.\n\nToll-free replay number: 1-800-770-2030\nReplay ID: 4126168\n\nAbout ChromaDex:\n\nChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. Follow us on Twitter @ChromaDex and subscribe to our latest news via our website accessible at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional updates and financial information about the Company.\n\nForward-Looking Statements:\n\nThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities and Exchan...